2-day In-person Seminar

Preparation of FDA Submissions and Communicating with the FDA (INDs, NDAs, BLAs, ANDAs, PMAs, 510(k)s, IDEs, Post-Approval Supplements)


June 20th & 21st, 2018

Time: 9:00 AM to 5:00 PM

Zurich Switzerland

Venue: Hilton Zurich Airport


Director : David Dills

**Please note the registration will be closed 2 days (48 Hours) prior to the date of the seminar.

  Price: $1,895.00
(Seminar Fee for One Delegate)

  Register for 5 attendees   Price: $5,685.00
      $9,475.00 You Save: $3,790.00 (40%)*

  Register for 10 attendees   Price: $10,422.00
      $18,950.00 You Save: $8,528.00 (45%)*
Course "Preparation of FDA Submissions and Communicating with the FDA (INDs, NDAs, BLAs, ANDAs, PMAs, 510(k)s, IDEs, Post-Approval Supplements)" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.

Why you should attend:

  • What do the regulations say?
  • Navigate the FDA drug and device approval system
  • Prepare, construct and submit well-written IND, NDA, BLA, PMA, 510(k) and IDE submissions and regulatory filings
  • Navigate the FDA review process
  • Identify the required regulations and guidance documents for drug and biologic submissions
  • Use regulations and guidance documents to outline and construct a variety of drug and biologic submissions
  • Formulate a working knowledge of regulatory submissions, publishing, and style guides
  • Create checklists that encompass timelines and sections needed from contributors
  • Strategic and technical guidance for drug and medical product development and regulatory review
  • Regulatory policy guidance
  • Regulatory Strategy planning and communications
  • FDA 510(k) submissions for obtaining FDA clearance
  • FDA Investigational Device Exemption (IDE) submissions for US clinical studies
  • FDA Requests for Classification and Requests for Determination
  • FDA Pre-Submission (Pre-sub) meetings
  • Attendees are encouraged to bring examples of their work from the functional area on the various topics as applicable for group discussion
  • Challenges and possible solutions will be discussed, and examples will demonstrate how the requirements can be put into practice
  • Where does the PMA fit into the medical device universe (e.g. how to decide whether to use the PMA or another pathway to market)?
  • How can the PMA be your friend (e.g. when a PMA is actually preferred over a 510k)?
  • What are the 'required contents' of a PMA submission?
  • How to decide amongst the types of PMA submissions (e.g. traditional, modular, streamlined, etc. and what are the advantages and disadvantages of each)?
  • What is the Summary of Safety and Effectiveness Data (SSED) and how is it used?
  • What are the differences in clinical trials for devices compared to drugs and biologics?
  • How can we design device clinical trials to maximize our success to market?
  • When can we combine pathways via label expansion?
  • Want to avoid the PMA? Consider the De Novo – using classification to your advantage!
  • How to use the PMA beyond the device world? i.e., using combination products: PMA+NDA/PMA+BLA, etc.
  • Define basic terms related to device research
  • Locate applicable regulations
  • Determine when an IDE is required
  • Describe Sponsor & Investigator responsibilities
  • Know contents and submission process for an IDE Application
  • Conduct IDE, PMA and 510(k) submission management activities
  • Regulatory strategy and regulatory planning for effective IND, NDA, ANDA and BLA submissions
  • Preparing for and conducting effective and efficient FDA meetings and communications
  • When to address and submit Post-Approval Supplements
  • Review and discuss pain points, challenges and solutions

Learning Bonus:

Upon completion of this course, attendees will have an understanding of the framework for FDA submission regulations and an approach on how to construct a submission. An appropriate submission strategy is necessary to legally manufacture a product in the US market. The course focuses on how a company’s product situation needs to be evaluated in order to determine the correct interpretation of the submission requirements. Emphasis will be placed not only on regulatory aspects, but on the overall medical device and drug product development strategy and environment. Creating an effective submission strategy will help your company avoid spending unnecessary time and money by avoiding an inappropriate path.


Who will benefit:

Personnel in the pharmaceutical, biopharmaceutical, biologics and generic drug industry who are involved in preparing FDA submissions (INDs, NDAs, BLAs, ANDAs, postapproval supplements) will find this course to be of particular benefit. Those who need to interact with FDA staff, including Project Managers, Regulatory Affairs, Clinical, Nonclinical, Manufacturing, and Quality personnel, will also find this course extremely useful.

This 510(k), PMA and IDE medical device submissions will be most valuable to medical device/product professionals who need an understanding of how to get medical devices into the US market while respecting FDA regulations. The course is geared toward professionals that are newer to the industry or who need to gain an understanding of submissions for the first time. Engineers, managers, supervisors, scientists, technicians, and other personnel involved in product development, manufacturing, quality assurance, or regulatory affairs that do not have an in-depth knowledge of medical device submissions will benefit from this course.

  • Research & Development Departments
  • Engineering Departments
  • Quality Assurance Departments
  • Regulatory Affairs Departments
  • New Product Development
  • Marketing Departments
  • Mid-level and Senior Management
  • Project Leaders
  • Professionals involved with premarket notification to the FDA
  • Consultants
  • Clinical Operations & Trial Management
  • Clinical Quality Assurance
  • Clinical Research Associate
  • Clinical Research Coordinator
  • Clinical Research Investigator
  • Data Management
  • Drug Safety
  • Engineering
  • Manufacturing
  • Marketing
  • Medical Affairs
  • Medical Writing
  • Nursing
  • Project Manager
  • Quality Control
  • Regulatory Affairs
  • Study Site Compliance
  • Training

Day 1 Schedule


Lecture 1:

Medical Devices

  • The recent changes in the 510(k) program and guidance documents relating to both 510(k)s and PMAs
  • How to identify and assess the regulatory requirements
  • How to meet the regulatory requirements in a systematic, integrative manner
  • How to increase a 510(k) and PMA submission quality
  • How to format succinct and comprehensive 510(k) and PMA submissions
  • When to submit a 510(k) for a new or modified product
  • Types of 510(k) submissions and when to use each
  • What is the submission process?
  • What is contained in a 510(k) submission package?
  • How to know whether clinical data is required.
  • How is the submission package assembled?
  • User fees and 510(k) submissions
  • How to interact with the FDA and the reviewer
  • What to do if you make a change to your device
  • What is "regulatory logic" and how can we use
  • it to our advantage?
  • What is and is not a regulated medical device?
  • How do we "design" or labeling (i.e., stated
  • claims vs. inferred/implied claims)?
  • How can we "advertise" off-label use?
  • What is competitive regulatory strategy (i.e., how can I use regulation as a barrier to entry to my competition)?
  • What is the medical device classification system?
  • Why do we have a classification system? Why is it important?
  • How do I determine classification?
  • Can I change classification?
  • How can I use classification to my advantage?
  • How does classification vary in other parts of the world?
  • What are the major pathways to market?
  • Premarket Notification a.k.a. 510k
  • Premarket Approval (PMA)
  • de Novo regulatory pathway and when to use it
  • Which do I choose and when?
  • Must I use only one? Can I mix and match?
  • What is the Pre-Market Notification (PMN) a.k.a., 510k?
  • How can I use the 510k to my advantage?
  • What does substantial equivalence really mean?
  • Why are many 510(k)'s rejected and how do I avoid being in the majority?
  • What types of 510k's exist and how do I choose?
  • What are the two most important components of a successful 510k?
  • When and how can I use the split- and multiple predicate strategies safely and effectively?
  • What is predicate creep?
  • If I change my device, must I tell FDA (special 510k vs. letter-to-file)?
  • What is the future of the 510k?
  • Steps to develop a PMA submission strategy
  • Best practices of quality system information for PMA applications
  • What to expect during a submission review
  • Preparation needed for an advisory panel meeting
  • Tips to prepare for an inspection
  • Ins and outs of BIMO inspections
  • How to deal with unexpected clinical outcomes, animal test results, and adverse panel recommendations
  • Needed supplemental submissions for approved PMAs
  • Where does the PMA fit in the medical device universe?
  • Why PMA's are rejected and how do I avoid being one of them?
  • How does the 510(k)compare to the PMA? Can I do both?
  • When is an IDE 'required' and when is it not (i.e., SR vs. NSR)?
  • What types of PMA's exist and how do I choose?
  • What goes into a successful PMA?
  • When do I need a clinical trial and how do I design one?
  • Key steps for the De Novo Pathway
  • What is the de novo and how does it compare to the 510k?
  • Why is the de novo the fastest growing pathway to market in the US?
  • How can I use the de novo to my competitive advantage?
  • Communication with FDA: The Pre-Submission Process
  • When and how should I communicate with FDA?
  • What is a pre-sub and should we use it?
  • What is a successful pre-sub and why are most not successful?
  • How early should we talk to FDA?
  • What do we need to include/should we include in the pre-sub?
  • Should we meet in person? How do we prepare?
  • What happens after the pre-sub? Are the results binding?
  • What are the regulatory challenges of combination products, tissue engineering and biomedical nanotechnology?
  • Where can I find additional information?
  • Definitions and Marketing Overview
  • Pre-Submission Meetings
  • Clinical Investigations of a Medical Device
  • IDE Exemption
  • Understand the application process and administrative action with your IDE
  • Know the responsibilities of the sponsor
  • IRB review and approval and expectations
  • What records and reports are expected and required
  • IDE refers to the regulations under 21 CFR 812
  • Know the procedures involved with the clinical studies and expectations
  • Understand that if the study involves a significant risk device, the IDE must also be approved by FDA
  • SR/NSR Determination and the IDE

Bonus Topics

The following topics are discussed throughout the course:

  • How do I integrate regulatory strategy and reimbursement strategy?
  • What goes into an international regulatory strategy
  • What is regulatory risk and how do I factor it into my regulatory strategy?
  • How can I use guidance documents to my competitive advantage?
  • What is usability and where does it fit into regulatory submissions?
  • What's the difference between writing a regulatory submission vs. designing a regulatory submission?
  • Learn the appropriate and expected regulatory strategies and guidelines for your drug and device submissions
  • Pre-submissions are made to the FDA in order to request FDA feedback
  • Pre-subs are used for various reasons including meeting requests, to study risk determination, for submission issues, and for FDA feedback to specific questions related to a pending submission or protocol
  • The de novo pathway for device marketing rights was added to address novel devices of low to moderate risk that do not have a valid predicate device
  • Upon successful review of a de novo submission, FDA creates a classification for the device, a regulation if necessary, and identifies any special controls required for future premarket submissions of substantially equivalent devices

Day 2 Schedule


Lecture 1:

Drugs/Biologics

  • Review and approval procedures for drug and biologics submissions/regulatory filings
  • Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. There are three IND types.
  • FDA Division Information: Submission Basics; Outlining the submission, creating the Table of Contents, timing of submission/timelines, contributions from other departments, editing, style guides, templates, supportive documents, QA’ing the submission
  • Publishing the Submission: Submission publishing basics; Copies (how many to make and keep); Introduction to electronic publishing requirements
  • Tracking the Submissions: Creating the index history; Creating an issues log
  • Common Technical Document Format Regular Copy
  • Pre-Market: FDA Meetings (Type A, B and C): Pre-IND, Phase I, Phase II, End of Phase II, requesting the meeting, preparing the meeting package, meeting minutes; The IND Submission; Routine IND Submissions: Clinical, Non-Clinical, CMC, Annual Reports, Investigator Brochure updates, protocol /protocol amendments, Investigators; Additional IND submissions: Fast track, orphan drug, special protocol assessment
  • Marketing Application: NDA in a CTD Format
  • NDA Forms and Electronic Submissions
  • Guidance Documents for NDA's and ANDA's
  • NDAs and BLAs: Filing Refusal to Accept Application for Filing From Applicants

Lecture 2:

Abbreviated New Drug Application (ANDA)

An abbreviated new drug application (ANDA) contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.

A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics, and intended use.

  • The Generic Drug Approval Process
  • What Is the Approval Process for Generic Drugs?

Lecture 3:

Biologics License Application (BLA)

The Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). The BLA is regulated under 21 CFR 600 – 680. A BLA is submitted by any legal person or entity who is engaged in manufacture or an applicant for a license who takes responsibility for compliance with product and establishment standards. Form 356h specifies the requirements for a BLA. This includes:

  • Applicant information
  • Product/Manufacturing information
  • Pre-clinical studies
  • Clinical studies
  • Labeling

Lecture 4:

Investigational New Drug (IND) Application

IND Process: FDA IND Form 1571; cover letter; table of contents; introduction; investigational plan; chemistry, manufacturing, and control; nonclinical studies (pharmacology and toxicology); clinical studies; investigator brochure; labeling; USAN procedures; compiling IND; IND filing; IND review process; amendments to IND; safety reports; annual reports; IND withdrawal; IND termination


Lecture 5:

New Drug Application (NDA)

NDA Process: FDA NDA Form 356(h); cover letter; index; labeling; summary; chemistry section (chemistry, manufacturing, and controls information; samples; methods validation package); nonclinical pharmacology and toxicology section; human pharmacokinetics and bioavailability section; clinical data section; safety update report; statistical section; case report tabulations; case report forms; patent information on any patent which claims the drug; patent certification; establishment description; debarment certification; field copy certification; user fee cover sheet; compiling NDA; NDA amendments; NDA review process; post-approval requirements

  • The resources for application reporting and applications procedures apply to IND applications for both clinical research and clinical treatment
  • Pre-Investigational New Drug Application (Pre-IND) Consultation Program
  • Legal Basis for FDA's Authority to Regulate Chemical Drugs, Biologics and Biopharmaceuticals
  • Overview of human medicine regulation by the FDA
  • Drug regulatory pathways granted to the FDA by U.S. Congressional laws
  • Human medicine distinctions: chemical drugs vs. biologics, CDER vs. CBER, generics vs. biosimilars
  • FDA Regulatory Drug Development Review and Approval Process
  • FDA's requirements/expectations for CMC, Nonclinical, Clinical content from Phase 1 through market approval
  • Differences in the FDA regulatory review and approval pathways for NDAs, BLAs, ANDAs and biosimilars
  • Accelerated and fast track FDA review opportunities
  • Meeting with the FDA
  • PDUFA, GDUFA and other meetings with the FDA - justified not entitled
  • Risk assessment - when should you have a meeting with the FDA
  • Lessons learned of what to do/not to do
  • Critical Importance of FDA Submissions and Communication during the IND Stage
  • What the FDA is looking for in IND submissions/amendments - avoiding the 'clinical hold'
  • Forms, format and content required during the clinical stages
  • Strategic value of the critical meeting with the FDA
  • Critical Importance of the FDA NDA/BLA/ANDA
  • Dossier Preparation
  • Need to avoid the Refusal to File
  • What the FDA is looking for in the market application dossier - forms, format, content
  • Strategic value of the Pre-NDA/BLA submission meeting with the FDA
  • FDA Review and Approval of the NDA/BLA/ANDA Submission
  • First milestone - avoiding the 'Refusal to File'
  • Intense interactions with the FDA covering CMC, Nonclinical and Clinical
  • Race to meet the time clock - avoiding the Complete Response Letter
  • Post-market Approval Submissions and Interactions with the FDA
  • Supplements for changes in CMC and Clinical, and required FDA reporting/updating
  • Honoring post-market approval commitments and ongoing adverse event reporting
  • Navigating the Rich FDA Website Resources
  • On-line resources for Drugs
  • On-line resources for Biologics
  • Insights into the FDA NDA/BLA review process

Lecture 6:

Case Study Practice

  • Practice on a project relevant to participants' organization

Lecture 7:

Interactive Exercises and Discussions

  • Drug and Medical Device Submissions and FDA Communications and Meetings

Recap of Day 2
Questions and Summary
Want to register by P.O/Check?
We facilitate registration by P.O/Checks!
Complete your registration in just a few easy steps
Please just download, fill out the registration form and send it to us either by email to support@globalcompliancepanel.com or just fax us at 302 288 6884.
Once the form is received, an invoice will be generated and sent back to your fax number.
Following this just send us your purchase order by fax at 302 288 6884
Click here to download Registration form
In case you wish to register by using check
In case you wish to register by using check, please make a check to NetZealous LLC DBA GlobalCompliancePanel.com and mail it to the below address.
NetZealous LLC,
DBA GlobalCompliancePanel,
161 Mission Falls Lane,
Suite 216, Fremont, CA 94539, USA
Phone: 1800 447 9407

Want to register by Wire Transfer?
Please call any of our representatives on 1800 447 9407 to help you completed the transfer.
Group participations
Get fabulous discounts by participating in groups of two or more.
No Attendees Discount
1 2 Attendees 10% off
2 3 to 6 Attendees 20% off
3 7 to 10 Attendees 25% off
4 10+ Attendees 30% off

To avail the above group discounts, all the participants should register by making a single payment

Call our representative TODAY on 1800 447 9407 to have your seats confirmed!

David R. Dills

Global Regulatory Affairs & Compliance Consultant and President, NovaQual

David R. Dills, Global Regulatory Affairs & Compliance Consultant, Interim President, currently provides global regulatory affairs, compliance and quality consultative services for early-stage and established Class I/II/III medical device, including combination products, In Vitro Diagnostics, nutraceuticals/supplements, cosmetics and biopharmaceutical manufacturers in multiple medical specialties and therapeutic areas on the global landscape, and has an accomplished record with more than 26 years of experience in the areas of Regulatory Affairs, Compliance and Quality Systems. He has been previously employed, with increasing responsibilities, by medical device manufacturers and consultancies, including a globally recognized CRO, and has worked directly with manufacturers engaged in compliance remediation activities and services involving consent decrees, CIA's, warning letters,483 observations, and customer generated compliance events. He prepares for and conducts QS and regulatory audits He is currently acting and interim President at NovaQual LLC.

He has been directly involved with constructing, reviewing, and/ or remediating regulatory submissions, including 510(k), PMA, IDE applications, IND, BLA and NDA submissions, preparing responses to AI's/deficiency letters, Supplements, Amendments, acting U.S. Agent, works closely with the key stakeholders and Agency/Center Reviewers regarding submission meetings and negotiations; clinical affairs and study submissions; and provides regulatory submissions and post-market project leadership and guidance covering different therapeutic and medical specialties based on classification.

Mr. Dills has a strong background in the interpretation and applicabilityofFDA regulations,including 21 CFR 210/211, 820 QSR/cGMP, Quality System implementation and compliance requirements, GxP training, leads and directs activitiesfor the registration and approval process andworking with Agencies in Asia Pacific, EU and The Americas, including but not limited to FDA, European Medicines Agency–EMA, MHRH, ANVISA, PMDA, MOH, SFDA, TGA, and Health Canada; and defining and executing regulatory compliance, risk mitigation and remediation strategies in response to inspection findings. Additional activities include Pre-FDA Facility Inspections, Mock Audits/Due diligence and assessing state of readiness for Pre-approval inspection (PAI/PMA), proof of management oversight, facilitate and direct efforts for remediation planning and monitoring, and assessment of the critical sub-systems, records and document controls; and strives for reduction of regulatory compliance risk for companies.

Directs and leads efforts for PM support and consultative services on behalf of manufacturers and subcontracted bythird-partyconsultancies and provides services involving all phases ofthe product development, submission, and commercialization process from premarketing to postmarketing; retained as U.S. Agent for international pharma and device clients; conducting supplier and QS audits/assessments; UDI compliance strategies; establishment registration and listing; Agency inspection readiness preparation and remediation; preparing Agency responses due to enforcement actions; conducting GxP audits and preparing CAP/remediation plans; compliance engineering support; support and/or lead efforts regarding Adverse Event, MDR, Incident Reporting, Postmarketing Surveillance and Vigilance Reporting; clinical affairs, establish and/or remediate Quality Management and documentation systems for GxP compliance; preparation for ISO13485 registration and CEMark; andmulti-countryproduct registrations and licensing.

Mr. Dills manages quality, regulatory and compliance projects with multiple competing priorities having a direct impact on site operations/commercial opportunities. Develops strategies for governmental approval to introduce new products to market, provides guidance and clarity on regulatory requirements, prepares and/or reviews submissions [e.g., NDA, ANDA, 510(k), PMA, IDE, CTD/CMC and BLA], including design dossiers and technical files, and other applications for Asia Pacific, The Americas and EU. Directs and leads efforts in establishing and retooling QA systems with emphasis on preventing the design, manufacture, and shipment of defective product; provide compliance engineering support; and lead efforts for GxP Strategic Compliance.

Mr. Dills manages regulatory problems (e.g. AE's, MDRs, Agency enforcement, and complaints) related to development, manufacturing, and commercialization, and recommends action to senior leadership to ensure effective resolution for manufacturers to achieve sustainable and proven compliant systems. Background encompasses broad capabilities in quality systems; documentation development and remediation; RA/RC oversight and governance; design controls; CAPA/investigations; GxP training; software and process validation with compliance oversight; supplier management; interfaces with FDA and other Agencies on the regulatory landscape; compliance with MDD/IVDD Directives and Technical File/Design Dossier and CE Mark requirements; conducts MDSAP training; and demonstrates credible experience to optimize business performance through proactive strategies to mitigate compliance exposure.

He also develops strategies and adds business value to manufacturers by providing strategic and tactical solutions that facilitate the achievement of regulatory and quality milestones and on minimizing delays due to noncompliance. He conducts Compliance, Governance, Assessments and Agency Mock Inspections; assist companies during FDA and other regulatory authorities' inspections and with post-inspection correspondence and meetings, involved in the product life cycle and commercialization process and works effectively across all functions for overall corporate compliance to support a company's goals and strategies.

Mr. Dills analyzes the benefits/risks for informed decision-making; interprets the regulatory precedents and new legislation; understands the competitive landscape; develops the business and regulatory approach; conductspersuasive communication with regulatoryauthorities;executes an effective path to approval; assists with GxP compliance strategies, effectively coordinates development in multiple markets; selects appropriate testing and manufacturing suppliers; and strives for overall corporate compliance withregulationsin The Americas, EMEA and Asia Pacific.

He provides direction on understanding the regulatory landscape for the product and provides a fully integrated approach to device development including design controls, and effective communications with Regulatory Authorities related to product development and post-marketing activities.

Mr. Dills has served on the Faculty Advisory Board for the Pharmaceutical Training Institute, Editorial Advisory Boards for Software Quality Professional and the Institute of Validation Technology (IVT), publisher of the Journal of GXP Compliance and Journal of Validation Technology and on the Readers' Board for Medical Device & Diagnostic Industry and Medical Product Manufacturing News and was nominated and accepted for inclusion into the 2005-2006 Strathmore's Who's Who of Professionals.

Mr. Dills has authored and published validation, regulatory and compliance-related articles, commentaries and technical guides, and is an accomplished global industry presenter. Mr. Dills' academic degrees include Environmental Science andBiology.Heis aformer Chair and Co- Chair of ASQ's Section 1506 and associated with the BiomedicalDivision,RAPS,AdvaMed, PDA, ISPE, and other industry working groups.

Location: Zurich, Switzerland Hotel: Hilton Zurich Airport   Hohenbuhlstrasse 10, 8152 Opfikon-Glattbrugg, Switzerland. +41 44 828 50 50

Sign Up for Our Newsletter